{"SPADE_N_14804": {"Sequence Information": {"Peptide Name": "Ilamycin B1, Rufomycin B1, Rufomycin I", "Sequence": "AXLXXXX", "Sequence Length": 7, "Biological Activity": ["Anti-Gram+", "Anti-Gram-", "Anticancer", "Anti-Mammalian Cell"], "Binding Target": "1. Cytoplasmic Protein", "Source": "1. Streptomyces atratus SCSIO ZH16", "Gene": "", "PDB ID": "6CN8_2", "UniProt Entry": [], "Literature": [{"Title": "Biosynthesis of Ilamycins Featuring Unusual Building Blocks and Engineered Production of Enhanced Anti-Tuberculosis Agents", "Pubmed ID": "28855504", "Reference": "Nat Commun. 2017;8:391", "Author": "Ma J, Huang H, Xie Y, Liu Z, Zhao J, Zhang C, Jia Y, Zhang Y, Zhang H, Zhang T, Ju J", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/28855504"}], "SPADE ID": "SPADE_N_14804", "Similar Sequences": [{"SPADE_ID": "SPADE_N_00017", "Similarity": 1.0, "Sequence": "TTWPCATVGVSVALCPTTKCTSQC"}, {"SPADE_ID": "SPADE_N_00019", "Similarity": 1.0, "Sequence": "GTPLALLGGAATGVIGYISNQTCPTTACTRAC"}, {"SPADE_ID": "SPADE_N_00020", "Similarity": 1.0, "Sequence": "TTPACFTIGLGVGALFSAKFC"}], "Hemolytic Activity": "Human hepatocyte cells HL-7702 (L02):IC50=>50 µM,Human umbilical vein endothelial cells HUVEC:IC50=>50 µM", "Target Organism": "Escherichia coli ATCC 25922(MIC=>126.5µM),Acinetobacter baumannii ATCC 19606(MIC=>126.5µM),Enterococcus faecalis ATCC 29212(MIC=>126.5µM),Staphylococcus aureus ATCC 29213(MIC=>126.5µM),Staphylococcus aureus MR(MIC=>126.5µM),Micrococcus luteus SC-1(MIC=>126.5µM),Mycobacterium smegmatis mc2-155(MIC=>126.5µM),Mycobacterium tuberculosis H37Rv(MIC=98.9µM),Human cervical carcinoma HeLa(IC50=>50µM),Human hepatocellular carcinoma HepG2(IC50=>50µM),Human lung carcinoma A549(IC50=>50µM),Human nasopharyngeal carcinoma CNE2(IC50=>50µM),Human breast adenocarcinoma MCF-7(IC50=>50µM)"}}}